Table of Contents
Jerome D. Cohen, MD, FACC, FACP
Background and Rationale for OTC Pravachol
Risk is Graded and Continuous Over Broad Range MRFIT (n=361,662)
Significant Proportion of Coronary Events Occur in Individuals with TC 200-240 mg/dl (MRFIT)
NCEP Guidelines - CHD Risk Factors Other Than LDL-C
Rationale for OTC Therapy
Rationale for OTC Therapy
Major Pravastatin Clinical Outcome Trials
WOSCOPS: Baseline Lipids and Outcome
CARE AND LIPID Baseline Lipids and Events*
Indications for Pravachol
Rationale for Pravachol OTC: Safety
PPT Slide
|
Author: mmedia3
|